HUE036147T2 - Adoptív sejtterápiában hasznos polipeptidek - Google Patents

Adoptív sejtterápiában hasznos polipeptidek

Info

Publication number
HUE036147T2
HUE036147T2 HUE13717833A HUE13717833A HUE036147T2 HU E036147 T2 HUE036147 T2 HU E036147T2 HU E13717833 A HUE13717833 A HU E13717833A HU E13717833 A HUE13717833 A HU E13717833A HU E036147 T2 HUE036147 T2 HU E036147T2
Authority
HU
Hungary
Prior art keywords
cell therapy
adoptive cell
polypeptides useful
polypeptides
useful
Prior art date
Application number
HUE13717833A
Other languages
English (en)
Hungarian (hu)
Inventor
Martin Pule
brian Philip
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of HUE036147T2 publication Critical patent/HUE036147T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
HUE13717833A 2012-04-13 2013-04-11 Adoptív sejtterápiában hasznos polipeptidek HUE036147T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206559.5A GB201206559D0 (en) 2012-04-13 2012-04-13 Polypeptide

Publications (1)

Publication Number Publication Date
HUE036147T2 true HUE036147T2 (hu) 2018-06-28

Family

ID=46209048

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13717833A HUE036147T2 (hu) 2012-04-13 2013-04-11 Adoptív sejtterápiában hasznos polipeptidek

Country Status (15)

Country Link
US (4) US10925943B2 (enExample)
EP (1) EP2836511B1 (enExample)
JP (1) JP6257584B2 (enExample)
CN (1) CN104379599B (enExample)
AU (1) AU2013246648B2 (enExample)
CA (1) CA2870233C (enExample)
DK (1) DK2836511T3 (enExample)
ES (1) ES2654144T3 (enExample)
GB (1) GB201206559D0 (enExample)
HU (1) HUE036147T2 (enExample)
NO (1) NO2836511T3 (enExample)
PL (1) PL2836511T3 (enExample)
PT (1) PT2836511T (enExample)
TR (1) TR201802560T4 (enExample)
WO (1) WO2013153391A1 (enExample)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673838B2 (ja) 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
CN106132423B (zh) 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
CN104849462B (zh) * 2014-02-17 2017-01-25 湖北大学 一种高灵敏度抗cd20单克隆抗体及其应用
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
ES2740903T3 (es) 2014-03-19 2020-02-07 Cellectis Receptores antigénicos quiméricos específicos de CD123 para inmunoterapia del cáncer
EP3137498A1 (en) 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
JP6868554B2 (ja) 2014-09-02 2021-05-12 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
UA123764C2 (uk) 2014-09-15 2021-06-02 МОЛМЕД СпА Химерний рецептор антигену та його застосування при лікуванні пухлин, які експресують cd44
CA2973529A1 (en) 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
JP6921001B2 (ja) 2015-04-13 2021-08-18 ファイザー・インク Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
WO2017025323A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
AU2016333886B2 (en) 2015-10-05 2020-10-08 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
EP4108255A1 (en) 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
US10259876B2 (en) 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
GB201614093D0 (en) 2016-08-17 2016-09-28 Autolus Ltd Vector
CN116970630A (zh) 2016-08-26 2023-10-31 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
EP3293199B1 (en) 2016-09-08 2021-01-13 Heinrich-Heine-Universität Düsseldorf Chimeric antigen receptors
WO2018058002A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
AU2017357649A1 (en) 2016-11-11 2019-05-23 Autolus Limited Chimeric antigen receptor
WO2018115189A1 (en) 2016-12-21 2018-06-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
EP3592379B1 (en) 2017-03-31 2024-04-24 Cellectis SA Universal anti-cd22 chimeric antigen receptor engineered immune cells
WO2018208837A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
MY201327A (en) 2017-06-02 2024-02-16 Pfizer Chimeric antigen receptors targeting flt3
GB201709203D0 (en) 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
AU2018292526A1 (en) 2017-06-30 2020-01-16 Precision Biosciences, Inc. Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
WO2019020733A1 (en) 2017-07-26 2019-01-31 Cellectis METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR)
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
JP7654240B2 (ja) 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
WO2019070856A1 (en) 2017-10-03 2019-04-11 Precision Biosciences, Inc. MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
EP3703710B9 (en) 2017-10-31 2024-12-04 Allogene Therapeutics, Inc. Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells for treating refractory and/or relapsed large b-cell lymphoma or refractory and/or relapsed follicular lymphoma
GB201720948D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
US20230158070A1 (en) 2018-01-30 2023-05-25 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
PE20251579A1 (es) 2018-02-01 2025-06-16 Pfizer Anticuerpos especificos para cd70 y sus usos
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
IT201800003464A1 (it) * 2018-03-13 2019-09-13 Ospedale Pediatrico Bambino Gesu Cellule T CAR-CD30 per il trattamento di tumori CD30+
WO2019200122A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
JP7447014B2 (ja) 2018-04-13 2024-03-11 サンガモ セラピューティクス フランス インターロイキン２３受容体に特異的なキメラ抗原受容体
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210268028A1 (en) 2018-07-02 2021-09-02 Cellectis Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
CN109265561B (zh) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用
EP3856775B9 (en) 2018-09-27 2025-01-22 Autolus Limited Chimeric antigen receptor
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
PE20211915A1 (es) 2018-12-01 2021-09-28 Allogene Therapeutics Inc Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
PH12021551861A1 (en) 2019-03-01 2022-05-30 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors
KR20210138574A (ko) 2019-03-01 2021-11-19 알로젠 테라퓨틱스 인코포레이티드 Dll3 표적화 키메라 항원 수용체 및 결합제
US11786553B2 (en) 2019-03-01 2023-10-17 Allogene Therapeuctics, Inc. Chimeric cytokine receptors bearing a PD-1 ectodomain
CN113543792A (zh) 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
AU2020240339A1 (en) 2019-03-21 2021-08-26 Allogene Therapeutics, Inc. Methods for enhancing TCRαβ+ cell depletion efficiency
CN116200342A (zh) 2019-04-03 2023-06-02 精密生物科学公司 包含microRNA适应的shRNA（shRNAmiR）的遗传修饰的免疫细胞
WO2020206231A1 (en) 2019-04-05 2020-10-08 Precision Biosciences, Inc. Methods of preparing populations of genetically-modified immune cells
GB201904971D0 (en) 2019-04-08 2019-05-22 Autolus Ltd Cell
WO2020219848A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Rituximab-resistant chimeric antigen receptors and uses thereof
WO2020219812A1 (en) 2019-04-26 2020-10-29 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP4004216A1 (en) 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
WO2021035054A1 (en) 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
US20210061881A1 (en) 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
GB201913258D0 (en) 2019-09-13 2019-10-30 Autolus Ltd Antigen-binding domain
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021113543A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
GB201918908D0 (en) 2019-12-19 2020-02-05 Autolus Ltd Cell
GB201919019D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Antigen-binding domain
MX2022008485A (es) * 2020-01-08 2022-08-02 Univ Texas Un metodo para modificar celulas asesinas naturales para dirigirse a tumores positivos a cd70.
TW202140533A (zh) 2020-01-16 2021-11-01 美商異基因治療有限公司 靶向B 細胞成熟抗原之嵌合抗原受體及γ 分泌酵素抑制劑之組合療法
AU2021227191A1 (en) 2020-02-24 2022-08-25 Allogene Therapeutics, Inc. BCMA car-T cells with enhanced activities
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
CA3173527A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
IL296411A (en) 2020-03-16 2022-11-01 Univ Southern California Novel antigen binding domains and synthetic antigen receptors incorporating them
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
US20230113183A1 (en) 2020-04-09 2023-04-13 Autolus Limited Cell
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
AU2021312871A1 (en) 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
EP4192875A1 (en) 2020-08-10 2023-06-14 Precision BioSciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
GB202013477D0 (en) * 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
US20230365995A1 (en) 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions
GB202017343D0 (en) 2020-11-02 2020-12-16 Autolus Ltd Cell
TW202227631A (zh) 2020-11-09 2022-07-16 英商圭爾醫療有限公司 冷凍保存經工程化之調節t細胞(tregs)之方法
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021401934A1 (en) 2020-12-14 2023-06-22 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
GB202019879D0 (en) 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
TW202246517A (zh) 2021-01-28 2022-12-01 美商異基因治療有限公司 用於轉導免疫細胞之方法
US20250127811A1 (en) 2021-01-28 2025-04-24 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
TW202245811A (zh) 2021-02-03 2022-12-01 美商異基因治療有限公司 用於ｃａｒ ｔ細胞藥物產品的調配物與製程
PE20241348A1 (es) 2021-09-01 2024-07-03 Springworks Therapeutics Inc Sintesis de nirogacestat
WO2023047098A2 (en) 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-p75ntr chimeric antigen receptor
EP4405385A1 (en) 2021-09-21 2024-07-31 Quell Therapeutics Limited Anti-trem2 chimeric antigen receptor
WO2023064872A1 (en) 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023091910A1 (en) 2021-11-16 2023-05-25 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
WO2023139360A1 (en) 2022-01-19 2023-07-27 Autolus Limited Nucleic acid construct
AU2023216270A1 (en) * 2022-02-04 2024-08-15 Nkilt Therapeutics, Inc. Chimeric ilt receptor compositions and methods
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
CA3254552A1 (en) 2022-04-28 2023-11-02 Allogene Therapeutics Inc METHODS FOR ANALYZING DONOR CELLS
EP4536853A1 (en) 2022-06-09 2025-04-16 Allogene Therapeutics, Inc. Methods for detecting genomic abnormalities in cells
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
WO2024026284A2 (en) * 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
EP4572774A1 (en) 2022-08-16 2025-06-25 Allogene Therapeutics, Inc. In vitro method for inhibiting hhv-6 infection
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
GB202219568D0 (en) 2022-12-22 2023-02-08 Autolus Ltd Chimeric antigen receptor
WO2024133472A1 (en) 2022-12-22 2024-06-27 Quell Therapeutics Limited Constitutive cytokine receptors
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
AU2024212695A1 (en) 2023-01-23 2025-08-14 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
AU2024240076A1 (en) 2023-03-20 2025-08-28 Autolus Limited A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma
WO2024194649A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t cells and uses thereof
WO2024194642A1 (en) 2023-03-22 2024-09-26 Quell Therapeutics Limited Engineered t regulatory cell
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
WO2024256823A1 (en) 2023-06-14 2024-12-19 Autolus Limited Treatment of trbc1-positive t cell malignancies
WO2024263710A1 (en) 2023-06-20 2024-12-26 Allogene Therapeutics, Inc. Methods of detection for engineered cells
WO2024261480A1 (en) 2023-06-21 2024-12-26 Quell Therapeutics Limited Constitutive cytokine receptors
GB202309704D0 (en) 2023-06-27 2023-08-09 Autolus Ltd Chimeric transmembrane protein
WO2025029606A1 (en) * 2023-07-28 2025-02-06 Beam Therapeutics Inc. Modified immune effector cells with improved resistance to natural killer cell-mediated allorejection
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
EP4512415A1 (en) 2023-08-24 2025-02-26 Medizinische Hochschule Hannover Chimeric antigen receptor for treatment of multiple sclerosis or alzheimer's disease
WO2025040799A1 (en) 2023-08-24 2025-02-27 Medizinische Hochschule Hannover Car for treatment of ms or ad
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
GB202405382D0 (en) 2024-04-16 2024-05-29 Ucl Business Ltd Chimeric antigen receptor
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US621147A (en) * 1899-03-14 Presser-foot for sewing-machines
EP2468291B1 (en) 2006-12-18 2017-11-22 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
JP4345819B2 (ja) 2007-01-19 2009-10-14 トヨタ自動車株式会社 エコドライブ支援装置、エコドライブ支援方法
TWI782836B (zh) * 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor

Also Published As

Publication number Publication date
US10925943B2 (en) 2021-02-23
GB201206559D0 (en) 2012-05-30
JP2015518479A (ja) 2015-07-02
US20240156926A1 (en) 2024-05-16
CN104379599B (zh) 2018-04-10
WO2013153391A1 (en) 2013-10-17
TR201802560T4 (tr) 2018-03-21
EP2836511A1 (en) 2015-02-18
US20150093401A1 (en) 2015-04-02
PT2836511T (pt) 2018-01-16
CA2870233A1 (en) 2013-10-17
AU2013246648A1 (en) 2014-11-06
US20250270279A1 (en) 2025-08-28
AU2013246648B2 (en) 2017-04-06
CA2870233C (en) 2023-03-28
ES2654144T3 (es) 2018-02-12
DK2836511T3 (en) 2018-03-05
PL2836511T3 (pl) 2018-06-29
EP2836511B1 (en) 2017-11-29
US20210308240A1 (en) 2021-10-07
CN104379599A (zh) 2015-02-25
NO2836511T3 (enExample) 2018-04-28
JP6257584B2 (ja) 2018-01-10

Similar Documents

Publication Publication Date Title
HUE036147T2 (hu) Adoptív sejtterápiában hasznos polipeptidek
IL288241A (en) Improved methods of cell culture for adoptive cell therapy
IL271005A (en) Improved methods of cell culture for adoptive cell therapy
DK3461491T3 (da) Forbedret adoptiv celleterapi
DK2900806T3 (da) Tredimensionel celledyrkning
GB2501358B (en) Closed cell materials
EP2850178A4 (en) EXOSOMES OF MESHCHYMIC STROKE CELL OF UMBILICAL CORD
EP2878161A4 (en) LOCATION IMPROVEMENT IN MULTIPLE PLMN DEPLOYMENTS
EP2858557A4 (en) IMPROVED REANIMATION
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
PL2817329T3 (pl) Polipeptydy wiążące z c5 ludzkiego dopełniacza
EP2927143A4 (en) RESIN VESSEL
GB201201100D0 (en) Polypeptides and methods
EP2808938A4 (en) BATTERY BLOCK
EP2819237A4 (en) AIR CELL
EP2927144A4 (en) RESIN VESSEL
LT2825565T (lt) Katijoninis polimeras glikogeno pagrindu
DK2920282T3 (da) Alkylenkoblede phenoler til anvendelse i biodieselmotorer
EP2818173A4 (en) CELL PREPARATION INCLUDING ADIPOSE CELL
PL2847811T3 (pl) Wieloczęściowy izolator ogniw akumulatorowych
KR102028919B9 (ko) 배터리 팩
DK3572090T5 (da) Korttidsvirkende faktor-vii-polypeptider
EP2874204A4 (en) Battery assembly
EP2830138A4 (en) BIOFUELS BATTERY
ZA201407276B (en) Polypeptides and their use